Publications

• 1. Kearns N
  2. Norville K
  3. Frelinger JG
  Instant Pot for antigen retrieval: a simple, safe and economical method for use in immunohistochemistry.; BioTechniques. 2023 May 18.
• 1. Norville K
  2. Skrombolas D
  3. Ferry SL
  4. Kearns N
  5. Frelinger JG
  A Protease Activatable Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research; Vol 42(7), pp. 316-328. 2022 Jul.
• 1. Bottaro A
  2. Brown DM
  3. Frelinger JG
  Editorial: The Present and Future of Immunology Education.; Frontiers in immunology; Vol 12. 2021.
• 1. Skrombolas D
  2. Sullivan M
  3. Frelinger JG
  Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2019 Mar 08.
• 1. Haidaris CG
  2. Frelinger JG
  Inoculating a New Generation: Immunology in Medical Education.; Frontiers in immunology; Vol 10. 2019.
• 1. Mikucki ME
  2. Skitzki JJ
  3. Frelinger JG
  4. Odunsi K
  5. Gajewski TF
  6. Luster AD
  7. Evans SS
  Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.; Oncoimmunology; Vol 5(5). 2016 May.
• 1. Skrombolas D
  2. Wylie I
  3. Maharaj S
  4. Frelinger JG
  Characterization of an IL-12 p40/p35 Truncated Fusion Protein That can Inhibit the Action of IL-12.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research; Vol 35(9). 2015 Sep.
• 1. Mikucki ME
  2. Fisher DT
  3. Matsuzaki J
  4. Skitzki JJ
  5. Gaulin NB
  6. Muhitch JB
  7. Ku AW
  8. Frelinger JG
  9. Odunsi K
  10. Gajewski TF
  11. Luster AD
  12. Evans SS
  Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.; Nature communications; Vol 6. 2015.
• 1. Skrombolas D
  2. Frelinger JG
  Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.; Expert review of clinical immunology; Vol 10(2). 2014 Feb.
• 1. Sedlacek AL
  2. Gerber SA
  3. Randall TD
  4. van Rooijen N
  5. Frelinger JG
  6. Lord EM
  Generation of a dual-functioning antitumor immune response in the peritoneal cavity.; The American journal of pathology; Vol 183(4). 2013 Oct.
• 1. Gerber SA
  2. Sedlacek AL
  3. Cron KR
  4. Murphy SP
  5. Frelinger JG
  6. Lord EM
  IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.; The American journal of pathology; Vol 182(6). 2013 Jun.
• 1. Gerber SA
  2. Sorensen EW
  3. Sedlacek AL
  4. Lim JY
  5. Skrombolas D
  6. Frelinger JG
  7. Lord EM
  Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.; Immunology; Vol 138(3). 2013 Mar.
• 1. Yokota SJ
  2. Facciponte JG
  3. Kelleher RJ
  4. Shultz LD
  5. Loyall JL
  6. Parsons RR
  7. Odunsi K
  8. Frelinger JG
  9. Lord EM
  10. Gerber SA
  11. Balu-Iyer SV
  12. Bankert RB
  Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.; Cancer immunity; Vol 13. 2013.
• 1. Valentino MD
  2. Abdul-Alim CS
  3. Maben ZJ
  4. Skrombolas D
  5. Hensley LL
  6. Kawula TH
  7. Dziejman M
  8. Lord EM
  9. Frelinger JA
  10. Frelinger JG
  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.; Journal of immunological methods; Vol 373(1-2). 2011 Oct 28.
• 1. Puskas J
  2. Skrombolas D
  3. Sedlacek A
  4. Lord E
  5. Sullivan M
  6. Frelinger J
  Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.; Immunology; Vol 133(2). 2011 Jun.
• 1. Valentino MD
  2. Maben ZJ
  3. Hensley LL
  4. Woolard MD
  5. Kawula TH
  6. Frelinger JA
  7. Frelinger JG
  Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.; Immunology; Vol 132(3). 2011 Mar.
• 1. Valentino MD
  2. Abdul-Alim CS
  3. Maben ZJ
  4. Skrombolas D
  5. Hensley LL
  6. Kawula TH
  7. Dziejman M
  8. Lord EM
  9. Frelinger JA
  10. Frelinger JG
  A broadly applicable approach to T cell epitope identification: Application to improving tumor associated epitopes and identifying epitopes in complex pathogens; Journal of Immunological Methods (in press). 2011 Jan 01.
• 1. Sorensen EW
  2. Gerber SA
  3. Frelinger JG
  4. Lord EM
  IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.; Journal of immunology (Baltimore, Md. : 1950); Vol 184(4). 2010 Feb 15.
• 1. Valentino M
  2. Frelinger J
  An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensis.; Immunologic research; Vol 45(2-3). 2009 Dec.
• 1. Valentino MD
  2. Hensley LL
  3. Skrombolas D
  4. McPherson PL
  5. Woolard MD
  6. Kawula TH
  7. Frelinger JA
  8. Frelinger JG
  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.; Molecular immunology; Vol 46(8-9). 2009 May.
• 1. Lugade AA
  2. Sorensen EW
  3. Gerber SA
  4. Moran JP
  5. Frelinger JG
  6. Lord EM
  Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.; Journal of immunology (Baltimore, Md. : 1950); Vol 180(5). 2008 Mar 1.
• 1. Malboeuf CM
  2. Simon DA
  3. Lee YE
  4. Lankes HA
  5. Dewhurst S
  6. Frelinger JG
  7. Rose RC
  Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo.; Vaccine; Vol 25(17). 2007 Apr 30.
• 1. Santos K
  2. Duke CM
  3. Rodriguez-Colon SM
  4. Dakwar A
  5. Fan S
  6. Keefer MC
  7. Federoff HJ
  8. Frelinger JG
  9. Bowers WJ
  10. Dewhurst S
  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.; Vaccine; Vol 25(9). 2007 Feb 19.
• 1. Santos K
  2. Simon DA
  3. Conway E
  4. Bowers WJ
  5. Mitra S
  6. Foster TH
  7. Lugade A
  8. Lord EM
  9. Federoff HJ
  10. Dewhurst S
  11. Frelinger JG
  Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.; Human gene therapy; Vol 18(2). 2007 Feb.
• 1. Ramanayake T
  2. Simon DA
  3. Frelinger JG
  4. Lord EM
  5. Robert J
  In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.; Transplantation; Vol 83(2). 2007 Jan 27.
• 1. Mitra S
  2. Cassar SE
  3. Niles DJ
  4. Puskas JA
  5. Frelinger JG
  6. Foster TH
  Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha.; Molecular cancer therapeutics; Vol 5(12). 2006 Dec.
• 1. Gerber SA
  2. Rybalko VY
  3. Bigelow CE
  4. Lugade AA
  5. Foster TH
  6. Frelinger JG
  7. Lord EM
  Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth.; The American journal of pathology; Vol 169(5). 2006 Nov.
• 1. Wagner VE
  2. Frelinger JG
  3. Barth RK
  4. Iglewski BH
  Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals.; Trends in microbiology; Vol 14(2). 2006 Feb.
• 1. Lugade AA
  2. Moran JP
  3. Gerber SA
  4. Rose RC
  5. Frelinger JG
  6. Lord EM
  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 174(12). 2005 Jun 15.
• 1. Gerber SA
  2. Turner MJ
  3. Lugade AA
  4. Moran JP
  5. Frelinger JG
  6. Lord EM
  Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.; The Prostate; Vol 63(2). 2005 May 1.
• 1. Bigelow CE
  2. Vishwasrao HD
  3. Frelinger JG
  4. Foster TH
  Imaging enzyme activity with polarization-sensitive confocal fluorescence microscopy.; Journal of microscopy; Vol 215(Pt 1). 2004 Jul.
• 1. Mitra S
  2. Goren EM
  3. Frelinger JG
  4. Foster TH
  Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo.; Photochemistry and photobiology; Vol 78(6). 2003 Dec.
• 1. Moran JP
  2. Gerber SA
  3. Martin CA
  4. Frelinger JG
  5. Lord EM
  Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.; International journal of cancer; Vol 106(5). 2003 Sep 20.
• 1. Gerber SA
  2. Moran JP
  3. Frelinger JG
  4. Frelinger JA
  5. Fenton BM
  6. Lord EM
  Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.; British journal of cancer; Vol 88(9). 2003 May 6.
• 1. Fisher TL
  2. Nocera M
  3. Willis RA
  4. Turner MJ
  5. Abdul Alim CS
  6. Brown DM
  7. Bourne PA
  8. di Sant'Agnese PA
  9. Messing EM
  10. Lord EM
  11. Frelinger JG
  Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.; The Prostate; Vol 51(3). 2002 May 15.
• 1. Patel D
  2. Frelinger J
  3. Goudsmit J
  4. Kim B
  In vitro assay for site-specific proteases using bead-attached GFP substrate.; BioTechniques; Vol 31(5). 2001 Nov.
• 1. Willis RA
  2. Bowers WJ
  3. Turner MJ
  4. Fisher TL
  5. Abdul-Alim CS
  6. Howard DF
  7. Federoff HJ
  8. Lord EM
  9. Frelinger JG
  Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.; Human gene therapy; Vol 12(15). 2001 Oct 10.
• 1. Turner MJ
  2. Abdul-Alim CS
  3. Willis RA
  4. Fisher TL
  5. Lord EM
  6. Frelinger JG
  T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.; Journal of immunological methods; Vol 256(1-2). 2001 Oct 1.
• 1. Brown DM
  2. Fisher TL
  3. Wei C
  4. Frelinger JG
  5. Lord EM
  Tumours can act as adjuvants for humoral immunity.; Immunology; Vol 102(4). 2001 Apr.
• 1. Skrincosky D
  2. Willis RA
  3. Hocknell PK
  4. Frelinger JG
  5. Mirandola P
  6. Wang X
  7. Dewhurst S
  Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies.; Archives of virology; Vol 146(9). 2001.
• 1. Egan RM
  2. Yorkey C
  3. Black R
  4. Loh WK
  5. Stevens JL
  6. Storozynsky E
  7. Lord EM
  8. Frelinger JG
  9. Woodward JG
  In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy.; Journal of immunology (Baltimore, Md. : 1950); Vol 164(9). 2000 May 01.
• 1. Lee J
  2. Moran JP
  3. Fenton BM
  4. Koch CJ
  5. Frelinger JG
  6. Keng PC
  7. Lord EM
  Alteration of tumour response to radiation by interleukin-2 gene transfer.; British journal of cancer; Vol 82(4). 2000 Feb.
• 1. Conway TF
  2. Sabel MS
  3. Sugano M
  4. Frelinger JG
  5. Egilmez NK
  6. Chen F
  7. Bankert RB
  Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.; Journal of immunological methods; Vol 233(1-2). 2000 Jan 13.
• 1. Martin BK
  2. Frelinger JG
  3. Ting JP
  Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.; Journal of immunology (Baltimore, Md. : 1950); Vol 162(11). 1999 Jun 1.
• 1. Storozynsky E
  2. Woodward JG
  3. Frelinger JG
  4. Lord EM
  Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.; Immunology; Vol 97(1). 1999 May.
• 1. Ostberg JR
  2. Barth RK
  3. Frelinger JG
  The Roman god Janus: a paradigm for the function of CD43.; Immunology today; Vol 19(12). 1998 Dec.
• 1. Wei C
  2. Callahan BP
  3. Turner MJ
  4. Willis RA
  5. Lord EM
  6. Barth RK
  7. Frelinger JG
  Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.; International journal of molecular medicine; Vol 2(4). 1998 Oct.
• 1. Yeh KY
  2. McAdam AJ
  3. Pulaski BA
  4. Shastri N
  5. Frelinger JG
  6. Lord EM
  IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.; Journal of immunology (Baltimore, Md. : 1950); Vol 160(12). 1998 Jun 15.
• 1. Lord EM
  2. Yeh KY
  3. Moran JA
  4. Storozynsky E
  5. Frelinger JG
  IL-3-mediated enhancement of particulate antigen presentation by macrophages.; Journal of immunotherapy (Hagerstown, Md. : 1997); Vol 21(3). 1998 May.
• 1. Lord EM
  2. Frelinger JG
  Tumor immunotherapy: cytokines and antigen presentation.; Cancer immunology, immunotherapy : CII; Vol 46(2). 1998 Apr.
• 1. Lee J
  2. Fenton BM
  3. Koch CJ
  4. Frelinger JG
  5. Lord EM
  Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.; Cancer research; Vol 58(7). 1998 Apr 1.
• 1. Willis RA
  2. Wei C
  3. Turner MJ
  4. Callahan BP
  5. Pugh AE
  6. Barth RK
  7. Lord EM
  8. Frelinger JG
  A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).; International journal of molecular medicine; Vol 1(2). 1998 Feb.
• 1. Ostberg JR
  2. Dragone LL
  3. Borrello MA
  4. Phipps RP
  5. Barth RK
  6. Frelinger JG
  Expression of mouse CD43 in the B cell lineage of transgenic mice causes impaired immune responses to T-independent antigens.; European journal of immunology; Vol 27(9). 1997 Sep.
• 1. Wei C
  2. Willis RA
  3. Tilton BR
  4. Looney RJ
  5. Lord EM
  6. Barth RK
  7. Frelinger JG
  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.; Proceedings of the National Academy of Sciences of the United States of America; Vol 94(12). 1997 Jun 10.
• 1. McEvoy LM
  2. Sun H
  3. Frelinger JG
  4. Butcher EC
  Anti-CD43 inhibition of T cell homing.; The Journal of experimental medicine; Vol 185(8). 1997 Apr 21.
• 1. Ostberg JR
  2. Dragone LL
  3. Driskell T
  4. Moynihan JA
  5. Phipps R
  6. Barth RK
  7. Frelinger JG
  Disregulated expression of CD43 (leukosialin, sialophorin) in the B cell lineage leads to immunodeficiency.; Journal of immunology (Baltimore, Md. : 1950); Vol 157(11). 1996 Dec 1.
• 1. Wei C
  2. Storozynsky E
  3. McAdam AJ
  4. Yeh KY
  5. Tilton BR
  6. Willis RA
  7. Barth RK
  8. Looney RJ
  9. Lord EM
  10. Frelinger JG
  Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.; Cancer immunology, immunotherapy : CII; Vol 42(6). 1996 Jul.
• 1. Pulaski BA
  2. Yeh KY
  3. Shastri N
  4. Maltby KM
  5. Penney DP
  6. Lord EM
  7. Frelinger JG
  Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.; Proceedings of the National Academy of Sciences of the United States of America; Vol 93(8). 1996 Apr 16.
• 1. McAdam AJ
  2. Pulaski BA
  3. Storozynsky E
  4. Yeh KY
  5. Sickel JZ
  6. Frelinger JG
  7. Lord EM
  Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.; Cellular immunology; Vol 165(2). 1995 Oct 15.
• 1. Yeh KY
  2. Pulaski BA
  3. Woods ML
  4. McAdam AJ
  5. Gaspari AA
  6. Frelinger JG
  7. Lord EM
  B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.; Cellular immunology; Vol 165(2). 1995 Oct 15.
• 1. McAdam AJ
  2. Pulaski BA
  3. Harkins SS
  4. Hutter EK
  5. Lord EM
  6. Frelinger JG
  Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.; International journal of cancer; Vol 61(5). 1995 May 29.
• 1. Dragone LL
  2. Barth RK
  3. Sitar KL
  4. Disbrow GL
  5. Frelinger JG
  Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival.; Proceedings of the National Academy of Sciences of the United States of America; Vol 92(2). 1995 Jan 17.
• 1. McAdam AJ
  2. Felcher A
  3. Woods ML
  4. Pulaski BA
  5. Hutter EK
  6. Frelinger JG
  7. Lord EM
  Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 15(3). 1994 Apr.
• 1. Woods ML
  2. McAdam AJ
  3. Frelinger JG
  4. Lord EM
  Isolation and expansion of tumor-infiltrating lymphocytes.; BioTechniques; Vol 15(6). 1993 Dec.
• 1. McAdam AJ
  2. Yeh KY
  3. Pulaski BA
  4. Frelinger JG
  5. Lord EM
  Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 14(4). 1993 Nov.
• 1. Pulaski BA
  2. McAdam AJ
  3. Hutter EK
  4. Biggar S
  5. Lord EM
  6. Frelinger JG
  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.; Cancer research; Vol 53(9). 1993 May 1.
• 1. Gaspari AA
  2. Ferbel B
  3. Frelinger JG
  Thy 1+ dendritic epidermal cells but not Langerhans cells express Ly 48.; The Journal of investigative dermatology; Vol 100(3). 1993 Mar.
• 1. Baecher-Allan CM
  2. Kemp JD
  3. Dorfman KS
  4. Barth RK
  5. Frelinger JG
  Differential epitope expression of Ly-48 (mouse leukosialin).; Immunogenetics; Vol 37(3). 1993.
• 1. McAdam AJ
  2. Blieden TM
  3. Frelinger JG
  4. Lord EM
  CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.; European journal of immunology; Vol 22(9). 1992 Sep.
• 1. Cerosaletti KM
  2. Woodward JG
  3. Lord EM
  4. Frelinger JG
  Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma.; Journal of immunology (Baltimore, Md. : 1950); Vol 148(4). 1992 Feb 15.
• 1. Dragone L
  2. Pallant A
  3. Insel R
  4. Frelinger JG
  CD43 is expressed normally on Wiskott-Aldrich-derived lymphocytes.; Experimental and clinical immunogenetics; Vol 9(3). 1992.
• 1. Blieden TM
  2. McAdam AJ
  3. Frelinger JG
  4. Lord EM
  Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 147(4). 1991 Aug 15.
• 1. Blieden TM
  2. McAdam AJ
  3. Foresman MD
  4. Cerosaletti KM
  5. Frelinger JG
  6. Lord EM
  Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors.; International journal of cancer. Supplement = Journal international du cancer. Supplement; Vol 6. 1991.
• 1. Dorfman KS
  2. Litaker W
  3. Baecher CM
  4. Frelinger JG
  The nucleotide sequence of Ly 48 (mouse leukosialin, sialophorin): the mouse homolog of CD43.; Nucleic acids research; Vol 18(16). 1990 Aug 25.
• 1. Phipps RP
  2. Baecher C
  3. Frelinger JG
  4. Penney DP
  5. Keng P
  6. Brown D
  Differential expression of interleukin 1 alpha by Thy-1+ and Thy-1- lung fibroblast subpopulations: enhancement of interleukin 1 alpha production by tumor necrosis factor-alpha.; European journal of immunology; Vol 20(8). 1990 Aug.
• 1. Pallant A
  2. Fukuda M
  3. Frelinger JG
  CD43 (leukosialin, sialophorin, large sialoglycoprotein) can be expressed in both normal and Wiskott-Aldrich fibroblasts via transfection of a leukosialin cDNA.; European journal of immunology; Vol 20(7). 1990 Jul.
• 1. Cerosaletti KM
  2. Blieden TM
  3. Harwell LW
  4. Welsh KM
  5. Frelinger JG
  6. Lord EM
  Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.; Cellular immunology; Vol 127(2). 1990 May.
• 1. Baecher CM
  2. Dorfman KS
  3. Mattei MG
  4. Frelinger JG
  cDNA cloning and localization of the mouse leukosialin gene (Ly48) to chromosome 7.; Immunogenetics; Vol 31(5-6). 1990.
• 1. Pallant A
  2. Eskenazi A
  3. Mattei MG
  4. Fournier RE
  5. Carlsson SR
  6. Fukuda M
  7. Frelinger JG
  Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.; Proceedings of the National Academy of Sciences of the United States of America; Vol 86(4). 1989 Feb.
• 1. Bahler DW
  2. Cerosaletti KM
  3. Lord EM
  4. Frelinger JG
  Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.; Journal of immunology (Baltimore, Md. : 1950); Vol 140(11). 1988 Jun 1.
• 1. Dennert G
  2. Landon C
  3. Lord EM
  4. Bahler DW
  5. Frelinger JG
  Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens.; Journal of immunology (Baltimore, Md. : 1950); Vol 140(7). 1988 Apr 1.
• 1. Baecher CM
  2. Infante AJ
  3. Semcheski KL
  4. Frelinger JG
  Identification and characterization of a mouse cell surface antigen with alternative molecular forms.; Immunogenetics; Vol 28(5). 1988.
• 1. Bahler DW
  2. Frelinger JG
  3. Harwell LW
  4. Lord EM
  Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection.; Proceedings of the National Academy of Sciences of the United States of America; Vol 84(13). 1987 Jul.
• 1. Sawicki JA
  2. Frelinger JG
  3. Palmer M
  4. Buck DA
  5. Dietzschold B
  6. Wettstein PJ
  Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes.; Journal of immunology (Baltimore, Md. : 1950); Vol 135(4). 1985 Oct.
• 1. Frelinger JG
  2. Shigeta M
  3. Fathman CG
  An analysis of monoclonal T cell and antibody recognition sites on Ia molecules.; The Journal of investigative dermatology; Vol 85(1 Suppl). 1985 Jul.
• 1. Frelinger J
  2. Sing A
  3. Infante A
  4. Fathman CG
  Clonotypic antibodies which stimulate T cell clone proliferation.; Immunological reviews; Vol 81. 1984 Oct.
• 1. Frelinger JG
  2. Shigeta M
  3. Infante AJ
  4. Nelson PA
  5. Pierres M
  6. Fathman CG
  Multiple functional sites on a single Ia molecule defined using T cell clones and antibodies with chain-determined specificity.; The Journal of experimental medicine; Vol 159(3). 1984 Mar 1.
• 1. Fathman CG
  2. Frelinger JG
  T-lymphocyte clones.; Annual review of immunology; Vol 1. 1983.
• 1. Beck BN
  2. Frelinger JG
  3. Shigeta M
  4. Infante AJ
  5. Cummings D
  6. Hämmerling G
  7. Fathman CG
  T cell clones specific for hybrid I-A molecules. Discrimination with monoclonal anti-I-Ak antibodies.; The Journal of experimental medicine; Vol 156(4). 1982 Oct 1.
• 1. Steinmetz M
  2. Moore KW
  3. Frelinger JG
  4. Sher BT
  5. Shen FW
  6. Boyse EA
  7. Hood L
  A pseudogene homologous to mouse transplantation antigens: transplantation antigens are encoded by eight exons that correlate with protein domains.; Cell; Vol 25(3). 1981 Sep.
• 1. Frelinger JG
  2. Hood L
  3. Wettstein P
  Analyses of RT1 products using two-dimensional polyacrylamide gels.; Transplantation proceedings; Vol 13(2). 1981 Jun.
• 1. Wettstein PJ
  2. Frelinger JG
  3. Hood L
  Serologic and biochemical analyses of rat class II molecules with anti-Ia sera.; Transplantation proceedings; Vol 13(2). 1981 Jun.
• 1. Steinmetz M
  2. Frelinger JG
  3. Fisher D
  4. Hunkapiller T
  5. Pereira D
  6. Weissman SM
  7. Uehara H
  8. Nathenson S
  9. Hood L
  Three cDNA clones encoding mouse transplantation antigens: homology to immunoglobulin genes.; Cell; Vol 24(1). 1981 Apr.
• 1. Frelinger JG
  2. Frelinger JA
  3. Hood L
  Peptide map comparisons of epidermal and spleen H-2 molecules.; Immunogenetics; Vol 12(5-6). 1981 Mar 1.
• 1. Wettstein PJ
  2. Frelinger JG
  3. Hood L
  Serological and biochemical characterization of rat (RT1) class II molecules with restricted mouse anti-Ia sera.; Immunogenetics; Vol 13(1-2). 1981.
• 1. Frelinger JA
  2. Frelinger JG
  Bone marrow origin of Ia molecules purified from epidermal cells.; The Journal of investigative dermatology; Vol 75(1). 1980 Jul.
• 1. Blankenhorn EP
  2. Cecka JM
  3. Frelinger J
  4. Götze D
  5. Hood L
  Structure of Ia antigens from the rat. Mouse alloantisera demonstrate at least two distinct molecular species.; European journal of immunology; Vol 10(2). 1980 Feb.
• 1. Frelinger JG
  2. Hood L
  3. Hill S
  4. Frelinger JA
  Mouse epidermal Ia molecules have a bone marrow origin.; Nature; Vol 282(5736). 1979 Nov 15.
• 1. Frelinger JG
  2. Motulsky H
  3. Woodward DO
  Effects of Chloramphenicol on the Circadian Rhythm of Neurospora crassa.; Plant physiology; Vol 58(4). 1976 Oct.